» Articles » PMID: 37893021

Synergistic Power of Piceatannol And/or Vitamin D in Bleomycin-Induced Pulmonary Fibrosis In Vivo: A Preliminary Study

Overview
Journal Biomedicines
Date 2023 Oct 28
PMID 37893021
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress and epigenetic alterations, including the overexpression of all class I and II histone deacetylases (HDACs), particularly HDAC2 and HDAC4, have been identified as key molecular mechanisms driving pulmonary fibrosis. Treatment with piceatannol (PIC) or vitamin D (Vit D) has previously exhibited mitigating impacts in pulmonary fibrosis models. The present study investigated the effects of PIC, Vit D, or a combination (PIC-Vit D) on the expression of HDAC2, HDAC4, and transforming growth factor-beta (TGF-β) in the lungs; the phosphatidylinositide-3-kinase (PI3K)/AKT signaling pathway; and the antioxidant status of the lungs. The objective was to determine if the treatments had protective mechanisms against pulmonary fibrosis caused by bleomycin (BLM) in rats. Adult male albino rats were given a single intratracheal dosage of BLM (10 mg/kg) to induce pulmonary fibrosis. PIC (15 mg/kg/day, oral (p.o.)), Vit D (0.5 μg/kg/day, intraperitoneal (i.p.)), or PIC-Vit D (15 mg/kg/day, p.o. plus 0.5 μg/kg/day, i.p.) were given the day following BLM instillation and maintained for 14 days. The results showed that PIC, Vit D, and PIC-Vit D significantly improved the histopathological sections; downregulated the expression of HDAC2, HDAC4, and TGF-β in the lungs; inhibited the PI3K/AKT signaling pathway; decreased extracellular matrix (ECM) deposition including collagen type I and alpha smooth muscle actin (α-SMA); and increased the antioxidant capacity of the lungs by increasing the levels of glutathione (GSH) that had been reduced and decreasing the levels of malondialdehyde (MDA) compared with the BLM group at a -value less than 0.05. The concomitant administration of PIC and Vit D had a synergistic impact that was greater than the impact of monotherapy with either PIC or Vit D. PIC, Vit D, and PIC-Vit D exhibited a notable protective effect through their antioxidant effects, modulation of the expression of HDAC2, HDAC4, and TGF-β in the lungs, and suppression of the PI3K/AKT signaling pathway.

Citing Articles

Cardioprotective Effects of α-Asarone Against Hexavalent Chromium-Induced Oxidative Damage in Mice.

Alwaili M, Elhoby A, El-Sayed N, Mahmoud I, Alharthi A, El-Nablaway M Drug Des Devel Ther. 2024; 18:3383-3397.

PMID: 39100222 PMC: 11297565. DOI: 10.2147/DDDT.S464334.

References
1.
Tsubouchi K, Araya J, Yoshida M, Sakamoto T, Koumura T, Minagawa S . Involvement of GPx4-Regulated Lipid Peroxidation in Idiopathic Pulmonary Fibrosis Pathogenesis. J Immunol. 2019; 203(8):2076-2087. DOI: 10.4049/jimmunol.1801232. View

2.
Tieyuan Z, Ying Z, Xinghua Z, Huimin W, Huagang L . Piceatannol-mediated JAK2/STAT3 signaling pathway inhibition contributes to the alleviation of oxidative injury and collagen synthesis during pulmonary fibrosis. Int Immunopharmacol. 2022; 111:109107. DOI: 10.1016/j.intimp.2022.109107. View

3.
P K, Sivashanmugam K, Kandasamy M, Subbiah R, Ravikumar V . Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors. Life Sci. 2020; 266:118883. PMC: 7831549. DOI: 10.1016/j.lfs.2020.118883. View

4.
Ma D, Peng L . Vitamin D and pulmonary fibrosis: a review of molecular mechanisms. Int J Clin Exp Pathol. 2020; 12(9):3171-3178. PMC: 6949840. View

5.
Ota C, Yamada M, Fujino N, Motohashi H, Tando Y, Takei Y . Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosis in vivo. Exp Lung Res. 2015; 41(8):422-34. DOI: 10.3109/01902148.2015.1060275. View